These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 39049766)

  • 1. The burden of adverse drug reactions reported by patients in the Dutch ADR monitor: a proof of concept.
    Quik JM; Gosselt HR; van Lint JA; Kosse LJ; Ten Klooster PM; Vonkeman HE; van den Bemt BJF; Jessurun NT
    Expert Opin Drug Saf; 2024 Jul; ():. PubMed ID: 39049766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-Reported Burden of Adverse Drug Reactions Attributed to Biologics Used for Immune-Mediated Inflammatory Diseases.
    van Lint JA; Jessurun NT; Hebing RCF; Hoentjen F; Tas SW; Vonkeman HE; van Doorn MBA; Sobels A; Spuls PI; van Puijenbroek EP; Nurmohamed MT; van den Bemt BJF
    Drug Saf; 2020 Sep; 43(9):917-925. PubMed ID: 32451974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patients' and health-care professionals' perspectives on adverse drug reaction burden attributed to the use of biological DMARDs: a qualitative study.
    Westerink HJ; Kosse LJ; Jessurun NT; Tubergen AV; Vonkeman HE; Nurmohamed MT; van den Bemt BJF; de Vries M
    Expert Opin Drug Saf; 2023; 22(5):417-424. PubMed ID: 36269284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discrepancy between patient- and healthcare provider-reported adverse drug reactions in inflammatory bowel disease patients on biological therapy.
    Thomas PWA; Römkens TEH; West RL; Russel MGVM; Jansen JM; van Lint JA; Jessurun NT; Hoentjen F
    United European Gastroenterol J; 2021 Oct; 9(8):919-928. PubMed ID: 34077634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recurring Fatigue After Biologic Administration: Patient-Reported Data from the Dutch Biologic Monitor.
    van Lint JA; Jessurun NT; Tas SW; Vonkeman HE; van Doorn MBA; Hoentjen F; Nurmohamed MT; van Puijenbroek EP; van den Bemt BJF
    BioDrugs; 2023 Jul; 37(4):541-550. PubMed ID: 37010772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sex differences in adverse drug reactions from Adalimumab and etanercept in patients with inflammatory rheumatic diseases.
    Gosselt HR; van Lint JA; Kosse LJ; Spuls PI; Vonkeman HE; Tas SW; Hoentjen F; Nurmohamed MT; van den Bemt BJF; van Doorn MBA; Jessurun NT
    Expert Opin Drug Saf; 2023; 22(6):501-507. PubMed ID: 36794307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Awareness, knowledge, attitude and practice of adverse drug reaction reporting among health workers and patients in selected primary healthcare centres in Ibadan, southwestern Nigeria.
    Adisa R; Omitogun TI
    BMC Health Serv Res; 2019 Dec; 19(1):926. PubMed ID: 31796034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse drug reactions for CAM and conventional drugs detected in a network of physicians certified to prescribe CAM drugs.
    Tabali M; Ostermann T; Jeschke E; Witt CM; Matthes H
    J Manag Care Pharm; 2012; 18(6):427-38. PubMed ID: 22839683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Global patterns of adverse drug reactions over a decade: analyses of spontaneous reports to VigiBase™.
    Aagaard L; Strandell J; Melskens L; Petersen PS; Holme Hansen E
    Drug Saf; 2012 Dec; 35(12):1171-82. PubMed ID: 23072620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis and visualization of the course and burden over time of adverse drug reactions (ADRs) attributed to TNFα-inhibitors in patients with inflammatory rheumatic diseases (IRDs).
    de Boer M; Gosselt HR; Jansen J; van Doorn MBA; Hoentjen F; Nurmohamed MT; Spuls PI; Tas SW; Vonkeman HE; Jessurun NT
    Expert Opin Drug Saf; 2023 Mar; 22(3):195-202. PubMed ID: 35946722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hospital admissions attributed to adverse drug reactions in tertiary care in Uganda: burden and contributing factors.
    Asio L; Nasasira M; Kiguba R
    Ther Adv Drug Saf; 2023; 14():20420986231188842. PubMed ID: 37529762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current Scenario and Future Prospects of Adverse Drug Reactions (ADRs) Monitoring and Reporting Mechanisms in the Rural Areas of India.
    Shukla S; Sharma P; Gupta P; Pandey S; Agrawal R; Rathour D; Kumar Kewat D; Singh R; Kumar Thakur S; Paliwal R; Sulakhiya K
    Curr Drug Saf; 2024; 19(2):172-190. PubMed ID: 37132145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantification of longitudinal patient-reported burden of adverse drug reactions attributed to the use of TNF-α inhibitors in inflammatory rheumatic diseases: an observational prospective cohort study.
    König BH; Gosselt HR; van Lint JA; Kosse LJ; van den Bemt BJF; Ten Klooster PM; Vonkeman HE; Jessurun NT
    Expert Opin Drug Saf; 2024 Aug; ():1-6. PubMed ID: 39041288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantifying the Severity of Adverse Drug Reactions Using Social Media: Network Analysis.
    Lavertu A; Hamamsy T; Altman RB
    J Med Internet Res; 2021 Oct; 23(10):e27714. PubMed ID: 34673524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Knowledge, awareness, perception and reporting of experienced adverse drug reactions among outpatients in Nigeria.
    Adisa R; Adeniyi OR; Fakeye TO
    Int J Clin Pharm; 2019 Aug; 41(4):1062-1073. PubMed ID: 31140162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spontaneous Reports of Serious Adverse Drug Reactions Resulting From Drug-Drug Interactions: An Analysis From the French Pharmacovigilance Database.
    Létinier L; Ferreira A; Marceron A; Babin M; Micallef J; Miremont-Salamé G; Pariente A;
    Front Pharmacol; 2020; 11():624562. PubMed ID: 33841134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison between paediatric and adult suspected adverse drug reactions reported to the European medicines agency: implications for pharmacovigilance.
    Blake KV; Zaccaria C; Domergue F; La Mache E; Saint-Raymond A; Hidalgo-Simon A
    Paediatr Drugs; 2014 Aug; 16(4):309-19. PubMed ID: 24898717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring drug safety in Astrakhan, Russia.
    Kirilochev OO; Dorfman IP; Umerova AR
    Int J Risk Saf Med; 2015; 27 Suppl 1():S33-4. PubMed ID: 26639700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The contribution of Ghanaian patients to the reporting of adverse drug reactions: a quantitative and qualitative study.
    Jacobs TG; Hilda Ampadu H; Hoekman J; Dodoo ANO; Mantel-Teeuwisse AK
    BMC Public Health; 2018 Dec; 18(1):1384. PubMed ID: 30563498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.